Acadia Pharmaceuticals Inc.
ACAD · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $1.07B | $958M | +11.9% |
| Operating income | $105M | $231M | −54.6% |
| Net income | $391M | $226M | +72.7% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 5, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $342M | $279M | +22.9% |
| Operating income | $71.7M | $35.8M | +100% |
| Net income | $53.5M | $71.8M | −25.5% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Acadia Pharmaceuticals's revenue in FY2025?
- $1.07B in FY2025 (Fiscal year ended Dec 31, 2025), +11.9% vs $958M a year earlier, per its 10-K filed Feb 2026.
- Was Acadia Pharmaceuticals profitable in FY2025?
- Yes: net income was $391M and operating income $105M in FY2025.
- What was Acadia Pharmaceuticals's revenue in Q3 2026?
- $342M (+22.9% vs a year earlier), per its Form 10-Q filed Nov 5, 2026.